**NM signifies a non meaningful value. A dash signifies the data is not available.

Developed under the direction and sponsorship of Gilead Sciences, Inc. At the AIDS 2024 congress ... the clinic and in the health systems to fight the HIV epidemic. Watch a summary of the symposium ...

Given as neoadjuvant treatment, TAR-200 plus cetrelimab generated responses in patients with muscle-invasive bladder cancer.

In Type 1 diabetes (T1D), insulin-producing β-cells are killed by islet-infiltrating immune cells in a process called “insulitis”. T1D results in a critical requirement for exogenous insulin and ...

Details The technical summary data tells us to buy GILD near 77.18 ... Updated AI-Generated Signals for Gilead Sciences Inc. (GILD) available here: GILD.

1 Investigators hypothesized that a side-by-side descriptive summary of efficacy with the approaches will ... Bristol Myers ...

Baylen, Paige Cowett, Rowan Niemisto, Dan Powell, Elisheba Ittoop, Marion Lozano and Alyssa Moxley Gilead delayed a new version of a drug, allowing it to extend the patent life of a ...

Gilead Sciences Inc.’s stock climbed 3% early Thursday after the company said its twice-yearly injection for HIV prevention cut infections by 96% in a late-stage trial, building the case for ...

Gilead Sciences’ Kite Pharma will sell its stake in China’s Fosun Kite Biotechnology nearly eight years after forming the 50-50 cell-therapy-focused joint venture with Fosun Pharma. Fosun ...

Chris Schott has given his Buy rating due to a combination of factors revolving around Gilead Sciences’ drug, lenacapavir, and its potential impact on the market. Schott points out the ...